References:

1. Taieb A, Khemis A, Ruzicka T, et al; Ivermectin Phase III Study Group. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. J Eur Acad Dermatol Venereol. 2016;30(5):829-836.

 

2. Taieb A, Ortonne JP, Ruzicka T, et al; Ivermectin Phase III Study Group. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172(4):1103-1110.

 

3. Stein Gold L, Kircik L, Fowler J, et al; Ivermectin Phase III Study Group. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13(3):316-323.

 

4. Data on file. Galderma Laboratories, L.P.

 

5. Deeks ED. Ivermectin: a review in rosacea. Am J Clin Dermatol. 2015;16(5):447-452.

 

6. Survey shows rosacea’s emotional toll, positive effects of medical therapy. Rosacea Review. Spring 2007. https://www.rosacea.org/rr/2007/spring/article_3.php. Accessed January 3, 2019.

 

7. Rosacea takes toll on sufferers in the workplace, survey shows. Rosacea Review. Summer 2011. https://www.rosacea.org/rr/2011/summer/article_3.php. Accessed January 3, 2019.